Klotho vs SS-31 (Elamipretide)
A side-by-side research comparison of Klotho and SS-31 (Elamipretide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Klotho | SS-31 (Elamipretide) |
|---|---|---|
| Full name | Klotho Protein | SS-31 / Elamipretide (Bendavia) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound (preclinical/early) | Investigational |
| Mechanism | Exists in membrane-bound and soluble forms. Soluble Klotho acts as a circulating hormone that modulates FGF23 signaling, regulates phosphate/vitamin D balance, suppresses certain growth and oxidative-stress pathways, and supports synaptic and cognitive function. | Targets cardiolipin in inner mitochondrial membrane, stabilizes cytochrome c binding, optimizes electron transfer efficiency, and reduces mitochondrial ROS by 50%. |
| Molecular weight | ~130 kDa (full protein; fragments studied) | 640.8 Da |
| Half-life | Not well established for therapeutic forms | 4-6 hours |
| Bioavailability | Injectable in research; large protein with limited oral absorption | High (SubQ) |
| Typical dose | No established human dose | 5-40 mg |
| Frequency | Unknown | Daily |
| Route | Injection (research) | Subcutaneous or IV |
Klotho reported benefits
- Associated with longevity and slower aging
- Neuroprotection and improved cognition (preclinical)
- Supports kidney and cardiovascular health
- Regulates phosphate and mineral balance
SS-31 (Elamipretide) reported benefits
- Mitochondrial function optimization
- Reduced oxidative stress
- Cardioprotection
- Improved exercise capacity
- Renal protection
- Cellular energy
Related comparisons
Research and educational reference only. Not medical advice.